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Introduction. Opioids are the most important drugs in treating pain in palliative care patients. Transdermal formulations are
especially useful due to their noninvasive nature andminimal interference in daily life. However, studies have shown a controversial
relationship of opioids to survival and a rise in deaths associated with the use of transdermal opioids. Although applying
precise doses is paramount, we have no clear recommendations for the exact equianalgesic ratio for buprenorphine patch and
no recommendation for the type of transdermal opioid to use in hospice. Methods. We analyzed the differences between the
transdermal fentanyl and buprenorphine group by analyzing patient characteristics and evaluating the differences in survival in
hospice patients over the age of 65, from 2013 to 2017.Results. A total of 292 patients (75.8%) used fentanyl patch and 93 (24.1%) were
on buprenorphine patch. Patients had virtually the same characteristics in both groups. However, when using a 1:100 buprenorphine
equianalgesic ratio, there were significant differences in initial and final doses, and it seems that a 1:80 conversion rate is more
accurate for elderly hospice patients. Finally, there was no difference in survival between the two groups using transdermal opioids,
with or without adjuvant analgesics.Discussion. Therewere no differences in survival between the group using transdermal fentanyl
and the group using buprenorphine in the elderly hospice population. Although adjuvant NSAIDs could be useful in the treatment
of pain in terminal cancer, they do not affect survival or reduce the opioid doses, while a 1:80 equianalgesic ratio of buprenorphine
might be the most appropriate in this population.
1. Introduction
Opioids are the essential drugs in treating pain in palliative
care patients [1]. Along with sedatives, antipsychotics, and
antimuscarinic drugs, they are considered as one of the four
essential drugs for dying patients [2]. However, there are
controversies for opioid use in the hospices, as studies have
shown that opioid use is associated with both longer and
shorter survival [3, 4]. One of the possible explanations for
such results might lie in a choice and formulation of the
opioid used, which is rarely analyzed. Transdermal (TD)
opioids are generally considered as safe and effective drugs,
often preferred over oral opioids, due to their noninvasive
nature, minimal interference with daily activities, and the
availability in patients who are unable to swallow or have
otherwise poor compliance [5, 6].
TDopioids are successfully used in the hospice setting [7],
both the fentanyl and the buprenorphine TD formulation.
However, the two drugs have very different pharmacology
[8] and are rarely directly compared. So far, there are no
recommendations of whether one formulation should have
an advantage over the other in the hospice setting. Of course,
quality of life and the level of pain should be the primary
concerns when choosing the opioid, but it is also important
to assess that these drugs do not have a negative effect on the
survival in the frail hospice population, especially knowing
there is a rise in deaths associated with the use of TD opioids
[9]. At-risk populations include cachectic cancer patients,
who have impaired absorption of the TD opioids [10], the
elderly due tomultiple comorbidities andmedicines used [11],
as well as patients with hepatic impairment [12], all of which
are common traits in hospice patients.
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An additional issue with the TD buprenorphine is that
there are no precise data for equipotency ratio of TD
buprenorphine to oral morphine, which is necessary to
calculate the needed dose for opioid conversion [13]. Current
research usually recommends using conversion rates from
70-75:1 for cancer patients [14, 15] to 110-115:1 for the mixed
population [16]. Such differences are potentially dangerous as
mismanagement of the dose could lead to either ineffective
pain reduction or respiratory depression, especially in frail
elderly hospice population. A more precise conversion rate
for this population is needed.
Since the hospice population is a mixed population, with
the predominantly elderly cancer patients, we hypothesize
that a conversion rate of buprenorphine of 1:100 is adequate.
We also hypothesize that there are no significant differences
in survival between the fentanyl and buprenorphine patches,
based on our empirical experience.
2. Methods
The study was a retrospective analysis of the patients enrolled
in the only Croatian hospice Marija K. Kozulic´, from March
2013 to March 2017. Although there is a variety of definitions
of an elderly patient, we used the common definition of
patients aged 65 years or older [17]. For patients to be included
in the research; they required an evaluation that estimated
survival time is less than three months and required to have
a medical confirmation that no further active treatment is
possible.
We analyzed the differences between the TD fentanyl
and buprenorphine by comparing patients characteristics
in both groups, analyzing the use of adjuvant analgesics
and sedatives, and evaluating the differences in survival
between the different patient groups. TD fentanyl patches
were changed every 3 days, while TD buprenorphine was
changed every 4 days, as per instructions.
The peroral opioids we used were morphine, oxycodone,
fentanyl, tramadol, and methadone, while the nonsteroidal
anti-inflammatory drugs (NSAIDs) used in the hospice were
ibuprofen, diclofenac, ketoprofen, metamizole, and paraceta-
mol. We used McPherson’s guide to convert different opioids
to Oral Morphine Equivalents (OME, mg/day) [18], while for
TD buprenorphine we used both 1:100 and 1:80 conversion
rates. Both NSAIDs and opioids were included in the study
as they were the only conventional pain medication used in
our population.
The performance score used is a Croatian patient catego-
rization system [19], where 1 denotes a completely indepen-
dent patient and 4 signifies a patient completely bedridden,
in the same manner as the ECOG scale [20]. Scores 2 to 3
describe patients dependent on a moderate or high degree,
depending on patient’s physical activity and self-care.
This research was approved by the Ethics Committee of
the Marija K. Kozulic´ Hospice and was undertaken adhering
to the highest ethical standards.
2.1. Statistics. We initially performed the Kolmogorov-
Smirnov test, which pointed us to use nonparametric tests.
Hence, Kruskal-Wallis ANOVA was used for comparing
multiple independent samples, while Mann-Whitney 𝑈 test
was used to compare two independent samples. Log-rank
test and Kaplan Meier method were used to analyze survival.
Descriptive analysis was performed to analyze general infor-
mation. We performed statistics using Statistica software 12
(StatSoft, USA).
3. Results
Initially, we assessed 902 patients enrolled in the hospice over
the examined period of 4 years. A total of 667 were older
than 65 years and were taken in further analysis. In this group
of patients, 385 were using transdermal opioids (57.7%), 88
(13.2%)were using only peroral opioids, while 194 (29.1%) did
not use any opioids.
The average age of our patients was 77.57 years, with
329 females (49.3%). High school was the highest level of
education for 344 (51.6%) of our patients, with themajority of
patients being married (N=295, 44.2%) or widowed (N=220,
32.9%).
The majority of patients (N=562, 84.3%) had cancer as
their primary diagnosis, with the most common cancer being
lung cancer (N=123, 18.4%), followed by gastrointestinal
cancers (N=122, 18.3%) and hepatobiliary cancers (N=74,
11.1%). If the patient did not have cancer, the most likely
diagnosis was the cerebrovascular injury (N=28, 4.2%). The
average performance score was 3.24 (±0.92), with a total of
347 (52.1%) patients evaluated as bedridden on admission.
On average, patients spent 17 days in the hospice. A total of
559 (83.8%) of the patients died in the hospice, while the rest
were discharged or transferred to other institutions.
Patients used two different formulations of TD opioids,
with 292 patients (75.8%) on the fentanyl patch and 93
(24.2%) on buprenorphine patch (Table 1). There were no
differences between the two groups regarding average age,
gender, the percentage of cancer patients, number of patient
deaths, dose elevations, dose reductions, or performance
score, which indicates that the two groups were very similar
in patient characteristics. Additionally, we observed no dif-
ferences in the concomitant use of peroral opioids, NSAIDs,
sedatives, or antipsychotics.
Although we did not assess the dose of all NSAIDs due
to difficulties in assessing generalised NSAIDs dose, we did
analyze the paracetamol dose between the two groups and
there were no significant differences recorded as 68 fentanyl
patients used paracetamol with an average dose of 1044 mg,
while 21 patients on buprenorphine used an average dose of
1057 mg paracetamol per day.
When we analyzed equianalgesic TD buprenorphine
dose as 1:100, there was a significant difference in starting
and final opioid doses among the two groups, which was
unexpected considering that both groups have virtually
the same patients characteristics. When we calculated the
buprenorphine equianalgesic ratio to 1:80, the OMEs were
similar between the two groups.
Finally, there was no difference in time spent in hos-
pice between the groups using fentanyl or buprenorphine
TD patch (16.40 versus 14.98 days). Although a trend was
present between the TD group and the group with only
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Table 1: Differences between patients on transdermal fentanyl and buprenorphine.
Parameter Fentanyl (1:100) Buprenorphine (1:100) Buprenorphine (1:80) Peroral opioids
Number of patients 292 93 88
Average age (yr) 76.27 ± 6.75 76.68 ± 6.59 78.64 ± 7.42
Female (%) 150 (51.4) 45 (48.4) 41 (46.6)
Cancer patients (%) 272 (93.1) 88 (94.6) 73 (82.9)
Number of patients died (%) 261 (89.4) 83 (89.2) 74 (84.1)
Initial opioid dose (OME) 105.21 ± 91.80 123.29 ± 104.46 102.11 ± 89.16 15.07 ± 17.47
Last opioid dose (OME) 144.30 ± 97.30 161.17 ± 104.02 133.76 ± 89.97 18.15 ± 18.63
Absolute difference 39.09 37.88 31.65 3.08
Percentage difference 37.1 23.5 30.99 20.4
Patients with dose elevation (%) 120 (41.1) 38 (40.8) 15 (17.0)
Patients with dose reduction (%) 3 (1.0) 1 (1.1) 3 (3.4)
Days in hospice ± SD 16.40 ± 19.36 14.98 ± 17.82 12.86 ± 15.78
Performance score ± SD 3.19 ± 0.96 3.25 ± 0.85 3.22 ± 0.92
Additional peroral opioids (%) 222 (76.0) 68 (73.1) n/a
Additional anxiolytic (%) 154 (52.7) 44 (47.3) 36 (40.9)
Additional NSAID (%) 108 (36.9) 33 (35.5) 47 (53.4)
Additional antipsychotic (%) 91 (31.2) 30 (32.2) 33 (37.5)
OME = oral morphine equivalent, mg/day. NSAID = nonsteroidal anti-inflammatory drugs.
The performance score is rated from 0 to 4, with 0 being fully mobile patients and 4 being bedridden patients.
Table 2: Differences in dosages and survival in patients with transdermal opioids with additional peroral analgesics (with an equianalgesic
ratio of 1:80 for buprenorphine).
Combination Number of patients Initial dose Final dose Diff. (%) Survival (SD) Performance score
Fentanyl + PO opioids 222 110.54 ± 97.66 154.77 ± 103.48 44.23 (40.0) 16.55 ± 19.28 3.15 ± 0.96
Buprenorphine + PO opioids 68 117.35 ± 95.49 151.74 ± 96.49 34.39 (29.3) 16.48 ± 19.14 3.26 ± 0.80
P value - 0.37 0.92 0.81 0.89 0.60
Fentanyl without PO opioids 70 88.28 ± 67.93 111.09 ± 64.50 22.80 (25.8) 15.91 ± 19.75 3.36 ± 0.92
Buprenorphine without PO opioids 25 60.67 ± 50.70 84.86 ± 40.39 24.19 (39.9) 10.88 ± 13.07 3.20 ± 1.00
P value - 0.68 0.74 0.57 0.22 0.48
Fentanyl + NSAID 108 107.36 ± 99.35 160.13 ± 104.27 52.77 (49.1) 19.76 ± 21.29 3.05 ± 0.95
Buprenorphine + NSAID 33 102.78 ± 78.09 140.33 ± 79.26 37.56 (36.5) 14.96 ± 13.20 3.24 ± 0.79
P value - 0.81 0.48 0.65 0.21 0.39
Fentanyl without NSAID 184 103.95 ± 87.33 135.01 ± 91.99 31.07 (29.89) 14.43 ± 17.89 3.28 ± 0.96
Buprenorphine without NSAID 60 101.75 ± 95.34 130.15 ± 95.80 28.39 (27.90) 14.98 ± 20.02 3.25 ± 0.89
P-value - 0.85 0.89 0.65 0.80 0.59
Doses are presented oral morphine equivalents, mg/day. NSAID = nonsteroidal anti-inflammatory drugs. PO = per oral. The performance score is rated from
0 to 4, with 0 being fully mobile patients and 4 being bedridden patients.
peroral opioids, the difference in survival was not statistically
significant.
We additionally analyzed the differences when TD opi-
oids were combined with peroral opioids and NSAIDs
(Table 2). Unsurprisingly, if the patients had additional
peroral opioids in therapy, they had a higher starting and
final OME dose per day. On the other hand, the addition
of NSAIDs did not alter either starting of final opioid dose.
However, no combination of adjuvant peroral opioids or
NSAIDs affected the length of stay in the hospice. There
was a trend of longer stay in the fentanyl + NSAIDs group.
However, this could be because this group had the best
performance score, which directly correlates to survival.
4. Discussion
To the best of our knowledge, our data represent the first
direct comparison of different TD opioids in a hospice
environment.
We initially calculated and compared buprenorphine to
fentanyl using a 1:100 conversion rate, since there are no
definite recommended conversion rates [13].The ratio of 1:100
we initially used for buprenorphine produced statistically
significant changes in opioid doses between the fentanyl and
buprenorphine group of patients. However, it is obvious from
Table 1 that there were virtually no differences in patient
characteristics between the two patient groups. Hence, it is
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likely that the patients were using similar OME doses. We
modified the analysis to use the 1:80 conversion rate for
buprenorphine, and judging by our results this is probably
the more appropriate conversion rate for elderly hospice
patients.
However, regarding safety, it was important to note
that there were no differences in survival between the two
groups, and both seem safe for hospice use in elderly. A
trend towards a longer survival with TD opioids, compared
to peroral ones, was observed but was not statistically
significant.
The safety did not differ evenwith the addition ofNSAIDs
or peroral opioids to TD opioids. Surprisingly, however, the
patients who used NSAIDs concomitantly did not have a
lower initial or final dose. This might support the thesis that
the only essential analgesics in the hospice are the opioids
(2).
Several weaknesses of the study need to be mentioned.
First of all, we did not analyze the quality of life or pain
ratings in this study, which is paramount for the choice of
opioid and the dose elevation. However, our goal here was
only to access the relationship of different TD opioids and
their combinations to survival, regardless of the effect on the
quality of life or symptoms such as constipation or delirium.
We also recognize that there may be unknown confounders
between the groups that receive opioids versus opioids plus
NSAIDs which may account for the lack of opioid sparing
effects. Additionally, this was a retrospective investigation,
enrolling only Caucasian patients and performed in only one
center. For future studies, to eliminate potential bias, we rec-
ommend performing a multicentric randomized prospective
investigation with a parallel analysis of the quality of life and
the doses and formulation of opioids.
5. Conclusion
This research supports the safety of both TD fentanyl and
buprenorphine in the hospice population. The choice of the
drug should depend on patient preferences, dosing schedule,
and the type of pain. Although adjuvant NSAIDs could be
useful in the treatment of pain in terminal cancer, they do
not affect survival or the reduce the opioid doses. Finally,
our data suggest that for elderly hospice patients, with cancer
as a dominant diagnosis, the 1:80-1:85 equianalgesic ratio of
buprenorphine might be more appropriate for conversion
purposes.
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